NCT00101231TerminatedPhase 1
A Dose Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Relapsed and Refractory Acute Leukemias
National Cancer Institute (NCI)1 site in 1 country88 target enrollmentStarted: October 2004Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- Maximal tolerable dose of flavopiridol
Study Overview
Brief Summary
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximal tolerable dose of flavopiridol in relapsed or refractory acute leukemia in adults (Stratum 1) and children (Stratum 2).
II. To define the qualitative and quantitative toxicities of flavopiridol in regard to organ specificity, time course, predictability, and reversibility.
III. To determine the preliminary clinical activity of flavopiridol in adults (Stratum 1) and children (Stratum 2) using this novel schedule in acute leukemia.
IV. To evaluate the plasma and cellular pharmacokinetics of flavopiridol in patients enrolled on this study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 1 Year to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed diagnosis of one of the following:
- •Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) meeting 1 of the following criteria:
- •Refractory to initial treatment (stratum 1)
- •Recurrent disease after prior high-dose chemotherapy with or without stem cell support (stratum 1)
- •High-risk refractory disease defined as failed ≥ 2 regimens for remission induction (i.e., twice induction failure) (stratum 2)
- •High-risk relaspsed disease defined as disease in second or greater bone marrow relapse (stratum 2)
- •Chronic myelogenous leukemia in blast crisis (stratum 1)
- •Myeloid or lymphoid blast crisis that did not respond to or progressed after prior high-dose imatinib mesylate (600-800 mg/day for ≥ 2 weeks)
- •No acute promyelocytic leukemia
- •Ineligible for or unwilling to undergo potentially curative allogeneic or autologous stem cell transplantation
- •Patients with relapsed AML that is refractory to re-induction therapy comprising an active, intensive salvage regimen are eligible
- •CNS involvement allowed provided there are no residual leukemic cells in the cerebrospinal fluid after intrathecal chemotherapy or radiotherapy
- •Performance status - ECOG ≥ 2 for patients > 10 years of age
- •Performance status - Lansky 50-100% for patients ≤ 10 years of age
- •At least 8 weeks
- •Bilirubin ≤ 2 times upper limit of normal (ULN)* (unless due to Gilbert's syndrome)
- •ALT and AST ≤ 5 times ULN*
- •Creatinine ≤ 2.0 mg/dL* (stratum 1)
- •Creatinine > 1.3 times ULN (stratum 2)
- •LVEF ≥ 40% by echocardiogram or MUGA (stratum 1)
- •Shortening fraction ≥ 28% by echocardiogram (stratum 2)
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No cardiac arrhythmia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •HIV negative
- •No history of allergy to study drug
- •No active infection requiring IV antibiotics
- •No serious medical or psychiatric illness that would preclude giving informed consent or limit survival
- •No other uncontrolled illness
- •See Disease Characteristics
- •Recovered from all prior immunotherapy treatment-related toxicity (stratum 2)
- •More than 8 weeks since prior biological agents (e.g., monoclonal antibodies) (stratum 2)
- •See Disease Characteristics
- •Recovered from all prior chemotherapy treatment-related toxicity (stratum 2)
- •More than 24 hours since prior hydroxyurea (for patients who do not have highly proliferative disease)*
- •More than 2 weeks since other prior chemotherapy (6 weeks for nitrosourea or mitomycin)
- •No other concurrent chemotherapy
- •Prior hydrea and/or steroids allowed (stratum 2)
- •No concurrent hormones, except steroids for adrenal failure or infusional toxicity (i.e., cytokine release syndrome) or hormones for non-disease-related conditions (e.g., insulin for diabetes)
- •See Disease Characteristics
- •Recovered from all prior radiotherapy treatment-related toxicity (stratum 2)
- •More than 2 weeks since prior radiotherapy
- •No concurrent palliative radiotherapy
- •Post stem cell transplant allowed provided completion ≥ 4 months prior to study entry and no evidence of active acute or chronic graft vs host disease (stratum 2)
- •No other concurrent investigational agents
- •No concurrent chronic systemic anticoagulant therapy for a medical condition (e.g., deep vein thrombosis or atrial fibrillation)
- •Concurrent heparin allowed to maintain central line patency (i.e., catheter flush)
- +1 more not shown
Exclusion Criteria
- Not provided
Arms & Interventions
Treatment (flavopiridol)
Experimental
Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
Intervention: alvocidib (Drug)
Outcomes
Primary Outcomes
Maximal tolerable dose of flavopiridol
Time Frame: Day 21
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaB-cell Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaWaldenström MacroglobulinemiaNCT00058240National Cancer Institute (NCI)52
Terminated
Phase 1
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaB-cell Chronic Lymphocytic LeukemiaContiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic LymphomaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic LymphomaNCT00377104National Cancer Institute (NCI)24
Terminated
Phase 1
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Multiple MyelomaSplenic Marginal Zone LymphomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple MyelomaWaldenström MacroglobulinemiaAnaplastic Large Cell LymphomaNCT00112723National Cancer Institute (NCI)46
Completed
Phase 1
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00079352National Cancer Institute (NCI)24
Terminated
Phase 1
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00112684National Cancer Institute (NCI)25